Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Huadong Medicine’s FGFR2b target ADC innovative drug HDM2020 China IND was approved by the NMPA Zhongmei Huadong, a subsidiary of Huadong Pharmaceutical, received NMPA approval to initiate […]
Weekly Digest – June 2025 Weekly Digest – June 2025 24 June 2025: Dong-A ST files IND for Phase 1 clinical trial of ADC candidate for cancer Dong-A ST’s ADC subsidiary, Aptis, has submitted an IND application in South Korea […]
Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Bio-Thera Solutions announce first patient dosed in Phase 3 clinical trial for BAT8006, an Antibody Drug Conjugate targeting folate receptor α for the treatment of platinum-resistant ovarian […]
Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Corbus Pharmaceuticals announces first patient dosed with its Nectin-4 targeting ADC CRB-701 in combination with pembrolizumab Corbus Pharmaceuticals has dosed the first participant in the PD-1 combination […]
Weekly Digest – June 2025 Weekly Digest – June 2025 17 June 2025: FDA grants orphan drug designation to Medicovestor’s first-in-class ADC for pancreatic cancer The FDA has granted Orphan Drug Designation to Medicovestor’s lead candidate, ADoBind MC001, for treating […]
Weekly Digest – June 2025 Weekly Digest – June 2025 17 June 2025: Boan receives FDA IND clearance for Its CD228-directed ADC Boan Biotech received FDA clearance to begin clinical trials in the U.S. for BA1302, a novel CD228-targeting ADC […]
Weekly Digest – June 2025 Weekly Digest – June 2025 16 June 2025: SunRock Biopharma and Escugen forge alliance to develop first-in-class CCR9-targeted ADC SunRock Biopharma and Escugen have partnered to co-develop SRB123, a first-in-class ADC targeting CCR9, an antigen […]
Weekly Digest – June 2025 Weekly Digest – June 2025 16 June 2025: NextCure and Simcere Zaiming announce strategic partnership for a novel antibody-drug conjugate targeting CDH6 NextCure and Simcere Zaiming have partnered to develop SIM0505, a novel CDH6-targeting ADC […]
Weekly Digest – June 2025 Weekly Digest – June 2025 18 June 2025: IDeate-Prostate01 Phase 3 trial of Ifinatamab Deruxtecan initiated in patients with pretreated metastatic castration-resistant prostate cancer The IDeate-Prostate01 Phase 3 trial has begun, evaluating Ifinatamab deruxtecan (I-DXd) […]
Weekly Digest – June 2025 Weekly Digest – June 2025 16 June 2025: Debiopharm’s ADC research gains momentum with launch of first-in-human trial assessing Debio 1562M in acute myeloid leukemia patients Debiopharm has dosed the first patient in a Phase […]
